Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a leading pharmaceutical company based in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its investigational drug, 177LuLNC1011. This novel therapeutic is a prostate specific membrane antigen (PSMA)-targeted radioactive in vivo treatment designed for prostate cancer.
Preclinical studies have demonstrated 177LuLNC1011’s PSMA targeting specificity and high affinity, which enables the concentration of radioactive isotopes directly on tumor lesions. This targeted approach promises precise treatment with favorable tolerability. The drug’s initial tolerability and safety profile, along with its significant preliminary therapeutic effects, position it as a potential alternative to the currently available PSMA-targeted therapy, Pluvicto, by Swiss pharmaceutical giant Novartis.- Flcube.com
